PK data analysis in dose-escalation phase indicated exposures of QRL-201 met or exceeded the targeted therapeutic range prompting advancement to the DRF phase ANQUR protocol amended to include additional biomarkers and cohort of participants with C9orf72-related ALS; Company to present…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.